Merck and Johnson & Johnson have reached a settlement in their dispute over the distribution rights for Remicade and Simponi, nearly two years after J&J requested arbitration in the case. Merck will give up marketing rights to both drugs in Canada, Central and South America, the Middle East, Asia and Asia Pacific territories. Those markets represented 30% of Merck’s Remicade and Simponi revenues. The company will retain exclusive rights in Europe, Russia and Turkey. Merck’...